Lilly Asia Ventures has returned for a series C round that boosted the total raised by the cancer and metabolic disease drug developer to $100m.
China-based oncology and metabolic drug developer InventisBio has completed a $70m series C round featuring Lilly Asia Ventures, a corporate venture capital subsidiary of pharmaceutical firm Eli Lilly.
The round was co-led by private equity fund Advantech Capital and financial services provider CMB International Capital Corporation and included asset management firm Pudong Innotek and OrbiMed Asia, a fund run by healthcare investment firm OrbiMed.
InventisBio is developing therapeutics to treat cancer and metabolic disease, and has advanced drugs for breast…
